CETUXIMAB AS PRIMARY TREATMENT FOR CUTANEOUS SQUAMOUS CELL CARCINOMA TO THE NECK

被引：21
|
作者：
Kim, Sung [1 ]
Eleff, Michael [2 ]
Nicolaou, Nicos [3 ]
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Canc Inst New Jersey, Hamilton, NJ USA
[3] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
来源：
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2011年 / 33卷 / 02期
关键词：
cutaneous; squamous cell carcinoma; SCC; metastatic; cetuximab; PLUS CETUXIMAB; HEAD; SKIN;
D O I：
10.1002/hed.21299
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Background. Head and neck cutaneous squamous cell carcinoma (SCC) metastatic to lymph nodes is commonly treated with surgery plus radiotherapy. Methods. We present the case of a 92-year-old man with cutaneous SCC metastatic to the neck (7 cm) who was treated with primary cetuximab and has had a durable complete response for 7 months. Because of his age, comorbidities, and unresectable neck lymphadenopathy, he received primary cetuximab. He received a 400 mg/m(2) loading dose and a 250 mg/m2 weekly dose for 3 months and then had to discontinue as a result of other unrelated medical issues. Results. The patient had a complete response by 6 weeks. Seven months after discontinuing cetuximab, he continues to have a complete response. Conclusions. Primary cetuximab for cutaneous SCC metastatic to lymph nodes is an area that bears further investigation because of its apparent efficacy and excellent toxicity profile. (C) 2009 Wiley Periodicals, Inc. Head Neck 33: 286 288, 2011
引用
收藏
页码：286 / 288
页数：3
相关论文
共 50 条
  • [1] Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab
    Berliner, Jacqueline G.
    Schulman, Joshua M.
    Lazarova, Zelmira
    Olasz, Edit
    Arron, Sarah T.
    DERMATOLOGIC SURGERY, 2019, 45 (02) : 313 - 316
  • [2] Cetuximab in the treatment of squamous cell carcinoma of the head and neck
    Specenier, Pol
    Vermorken, Jan B.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (04) : 511 - 524
  • [3] Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Greenhalgh, J.
    Bagust, A.
    Boland, A.
    Fleeman, N.
    McLeod, C.
    Dundar, Y.
    Proudlove, C.
    Shaw, R.
    HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 : 49 - 54
  • [4] Cisplatin and Cetuximab Treatment for Metastatic Cutaneous Squamous Cell Carcinoma: A Systematic Review
    Trodello, Cameron
    Pepper, Jon-Paul
    Wong, Michael
    Wysong, Ashley
    DERMATOLOGIC SURGERY, 2017, 43 (01) : 40 - 49
  • [5] Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma
    Zhang, E. J.
    Knox, M.
    Veness, M. J.
    Abdul-Razak, M.
    Wong, E.
    Hwang, E. J.
    Carlino, M.
    Sundaresan, P.
    CLINICAL ONCOLOGY, 2025, 38
  • [6] Spotlight on Cetuximab in Squamous Cell Carcinoma of the Head and Neck
    Frampton, James E.
    BIODRUGS, 2011, 25 (02) : 129 - 133
  • [7] Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
    Maseki, Shinichiro
    Ijichi, Kei
    Nakanishi, Hayao
    Hasegawa, Yasuhisa
    Ogawa, Tetsuya
    Murakami, Shingo
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (05) : 918 - 924
  • [8] Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
    Perri, Francesco
    Longo, Francesco
    Ionna, Franco
    Caponigro, Francesco
    ONCOTARGETS AND THERAPY, 2009, 2 : 243 - 250
  • [9] Toxicity of Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma Treatment
    Torres, S.
    Sargento, I.
    Ferreira, M.
    Oliveira, J. O. A. O.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S552 - S552
  • [10] Cutaneous squamous cell carcinoma of the head and neck
    Deutsch, Jochen
    Dippel, Edgar
    Delank, K. -Wolfgang
    LARYNGO-RHINO-OTOLOGIE, 2023, 102 (03) : 186 - 193
12345